IN VIVO ISOLATION OF CTCs







CUTTING EDGE TECHNOLOGY

- In vivo isolation of CTCs from the whole volume of peripheral blood
- Technology taking advantage of magnetic nanoparticles coated with a monoclonal antibody that are injected into the bloodstream via an intravenous cannula, as well as of a special wire comprising a magnetic core coated with a non-magnetic mantle

STAGE OF PROTECTION AND DEVELOPMENT

- Granted European patent (EP3052026 (B1))
 validated in Germany and France
- Granted Slovak patent (No. 288562)
- TRL 2 technology concept and/or application formulated

APPLICATIONS

Molecular diagnostics of cancer and personalised medicine

COMPETITIVE TECHNOLOGY


- In vivo isolation of CTCs and/or CSCs
- Isolation of CTCs and/or CSCs from the whole volume of patient's blood
- Detection of CTCs and/or CSCs in very low concentrations
- More effective than available solutions
- Universal solution that may be adapted to any type of blood cells
- Easy and straightforward manipulation

THE INVENTORS ARE LOOKING FOR AN INDUSTRIAL PARTNER FOR FURTHER DEVELOPMENT AND FOR LICENSING THE TECHNOLOGY


TECHNICAL DETAILS

Principle of function:

 Magnetic nanoparticles coated with a monoclonal antibody are injected into the vein through a venous cannula, while their position is controlled using magnets



- The nanoparticles are exposed to circulating tumor cells
- After in vivo incubation the nanoparticles are moved closer to the venous cannula by the movement of large magnets and a special wire comprising a magnetic core coated with a non-magnetic mantle is inserted through the cannula into the blood stream
- Large magnets are removed and nanoparticles are attracted by the magnetic wire



- Magnetic wire coated with nanoparticles with attached CTCs is removed from the cannula and placed in a test tube with a suitable medium
- The magnetic core is removed and the nanoparticles with attached CTCs are released into the medium for further analysis

FOR MORE INFORMATION PLEASE CONTACT

Ing. Martin Gróf, PhD. phone: +421 904 983 265 email: grof.martin@savba.sk



The inventors use services of Technology Transfer Office of Slovak Academy of Sciences to market their invention.